Paying users zone. Data is covered by .

  • Get to Bristol-Myers Squibb Co. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

 

$15.99


Free Cash Flow to The Firm (FCFF)

Bristol-Myers Squibb Co., FCFF calculation

USD $ in millions

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net earnings attributable to BMS
Noncontrolling interest
Net noncash charges
Changes in operating assets and liabilities
Net cash provided by operating activities
Interest payments, net of tax1
Capital expenditures
Free cash flow to the firm (FCFF)
Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the Bristol-Myers Squibb Co.'s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. Bristol-Myers Squibb Co.'s FCFF increased from 2015 to 2016 and from 2016 to 2017.

Top


Interest Paid, Net of Tax

Bristol-Myers Squibb Co., interest paid, net of tax calculation

USD $ in millions

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Effective Income Tax Rate (EITR)
EITR1 % % % % %
Interest Paid, Net of Tax
Interest payments, before tax
Less: Interest payments, tax2
Interest payments, net of tax

2017 Calculations

2 Interest payments, tax = Interest payments × EITR
= × % =

Top


Enterprise Value to FCFF Ratio, Current

Bristol-Myers Squibb Co., current EV/FCFF calculation, comparison to benchmarks

 
Selected Financial Data (USD $ in millions)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals & Biotechnology
EV/FCFF, Industry
Health Care

If company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.

Otherwise, if company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.

Top


Enterprise Value to FCFF Ratio, Historical

Bristol-Myers Squibb Co., historical EV/FCFF calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in millions)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Celgene Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals & Biotechnology
EV/FCFF, Industry
Health Care

2017 Calculations

3 EV/FCFF = EV ÷ FCFF
= ÷ =

Ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. Bristol-Myers Squibb Co.'s EV/FCFF ratio declined from 2015 to 2016 and from 2016 to 2017.

Top